Newer Antidepressants Compared: Vortioxetine, Vilazodone, Auvelity and Zuranolone

The four newer antidepressants people ask about most are vortioxetine (Trintellix), vilazodone (Viibryd), dextromethorphan-bupropion (Auvelity) and zuranolone (Zurzuvae). The first three are FDA-approved for major depressive disorder in adults; zuranolone is approved only for postpartum depression, as a 14-day course. Newer does not mean stronger: a systematic review comparing vortioxetine and vilazodone with other second-generation antidepressants found similar efficacy and no clear evidence of greater benefit or fewer harms. They tend to come up after a first-line drug has not worked or has caused side effects that a different mechanism might avoid.

Each has a distinct mechanism and side-effect profile, which is the real reason to know about them. This guide covers what each is approved for, when clinicians tend to consider it, what the evidence does not show, and what to ask about coverage. Decisions about starting or switching belong with your prescriber.

The four at a glance

Vortioxetine (Trintellix)

Vortioxetine inhibits serotonin reuptake and also acts on several serotonin receptors, including 5-HT3 antagonism and 5-HT1A agonism, though the label says the contribution of these extra actions to its antidepressant effect has not been established. It was first approved in 2013 for major depression in adults.

Nausea is the signature side effect and the most common reason people stopped it in trials; constipation and vomiting are also common. Its mean terminal half-life is about 66 hours, and the label says it can be stopped abruptly, though it recommends stepping down from the higher doses for a week first because some people had transient headache and muscle tension after abrupt stopping. Vortioxetine is processed partly by CYP2D6: the maximum recommended dose is lower in known poor metabolizers, and the dose is halved with strong CYP2D6 inhibitors such as bupropion or fluoxetine.

The cognition question

You may hear that vortioxetine helps thinking and concentration. Its label describes two 8-week trials in which people with depression on vortioxetine improved more than those on placebo on the Digit Symbol Substitution Test, a measure of processing speed; mood also improved in both studies, and neither study included people whose depression was in remission but who still had concentration problems. That leaves open how much of the effect is separate from mood improvement, and it does not show benefit for "brain fog" outside an active depressive episode.

Where it tends to fit

In the 2018 network meta-analysis, vortioxetine was among the drugs with better results in head-to-head trials and among the more tolerable ones, though certainty was moderate to very low. Prescribers may consider it when an SSRI caused sexual side effects or when cognitive complaints are prominent, but its label still lists sexual dysfunction as a possible effect and says comparative studies have not shown an advantage over other antidepressants on the processing-speed test.

Vilazodone (Viibryd)

Vilazodone combines serotonin reuptake inhibition with partial agonism at 5-HT1A receptors, and was approved in 2011 for major depression in adults. It must be taken with food, which matters for absorption, and the label describes a stepwise start over the first weeks. Diarrhea, nausea, vomiting and insomnia are the most common side effects. The label recommends tapering when stopping and limits the dose when it is combined with strong CYP3A4 inhibitors such as clarithromycin or itraconazole.

The 5-HT1A action does not exempt it from sexual side effects: the label lists sexual dysfunction as a warning, and a systematic review of vilazodone, vortioxetine and levomilnacipran found no clear evidence of greater benefit or fewer harms than other second-generation antidepressants, with low strength of evidence for most outcomes. The only head-to-head trials for vilazodone in that review compared it with citalopram; vortioxetine had been compared directly with duloxetine, paroxetine and venlafaxine XR.

Dextromethorphan-bupropion (Auvelity)

Auvelity pairs dextromethorphan, an NMDA receptor antagonist and sigma-1 agonist, with bupropion. Bupropion inhibits CYP2D6, which slows dextromethorphan's breakdown and raises its levels. It was approved in 2022 for major depression in adults and, in April 2026, its label added agitation associated with dementia due to Alzheimer's disease.

Its most notable feature is speed in trials. In the main 6-week placebo-controlled study, the difference from placebo on the MADRS depression scale was statistically significant at week 1 and week 2, both prespecified secondary endpoints. A second trial compared it with bupropion alone at the same bupropion dose, and the label says the results showed that dextromethorphan contributes to the antidepressant effect. These are short trials; they do not show that earlier improvement is sustained differently over months.

Who should not take it

Because it contains bupropion, Auvelity is contraindicated in people with a seizure disorder, a current or past diagnosis of bulimia or anorexia nervosa, and within 14 days of an MAOI. It can raise blood pressure, so blood pressure is checked before starting and periodically, and the label also warns about dizziness and falls. Prescribers screen for bipolar disorder and check for other medicines containing bupropion or dextromethorphan, including some cough products. Dosing is lower in moderate kidney impairment, in known CYP2D6 poor metabolizers and with strong CYP2D6 inhibitors.

Zuranolone (Zurzuvae)

Zuranolone is a neuroactive steroid that is thought to work by enhancing GABA-A receptors. The FDA approved it on 4 August 2023 as the first oral medication indicated for postpartum depression in adults. It is not approved for major depression outside the postpartum period.

The course is short: once each evening with fat-containing food for 14 days, and safety and effectiveness beyond 14 days in a single course have not been established. In both pivotal trials, people on zuranolone improved significantly more than those on placebo on the HAMD-17 at day 15.

Its boxed warning is about driving: people should not drive or do other hazardous activities until at least 12 hours after each dose, and may not be able to judge their own impairment. It is a Schedule IV controlled substance, may cause fetal harm, and the label advises effective contraception during treatment and for one week after the last dose. Before zuranolone, the only FDA-approved drug specifically for postpartum depression was the intravenous infusion brexanolone (Zulresso), whose approval was withdrawn as of 14 April 2025 at the manufacturer's request after it was no longer marketed. For the full set of options, including therapy and standard antidepressants, see postpartum depression treatment options.

Other newer options you may hear about

Esketamine is a different kind of decision, usually considered after several treatments have not worked; what a psychiatrist considers when two antidepressants haven't worked covers it alongside other options.

When clinicians consider a newer antidepressant

Prescribers often start with an established option such as an SSRI, an SNRI, bupropion or mirtazapine, which have long track records and generic versions. Newer drugs tend to come up in specific situations:

• A first or second antidepressant did not help enough, and the next step is a switch rather than an add-on. See switching antidepressants.
• A side effect, such as sexual dysfunction, emotional blunting or weight gain, ended an otherwise helpful drug, and a different mechanism might avoid it.
• Depression has followed childbirth, which is the only setting in which zuranolone is approved.
• Faster onset matters and there is no seizure or eating disorder history, which may bring Auvelity into the discussion.
• Interactions or other health conditions rule out the usual choices.

None of these drugs has been shown to work better on average than established antidepressants. For vortioxetine and vilazodone, the systematic review found similar efficacy and rated the strength of evidence as low for most outcomes; Auvelity's comparison trial was against bupropion alone, and zuranolone has been compared only with placebo. What they offer is a different profile, which can matter a great deal for one person.

What the evidence does not show

• That any of these is more effective than generic options for a typical adult with depression.
• That vortioxetine improves concentration independently of mood, or in people without active depression.
• That Auvelity's earlier separation from placebo in a 6-week trial translates into better long-term outcomes.
• That zuranolone helps depression outside the postpartum period, or works beyond a single 14-day course.
• That any of them is free of the class boxed warning about suicidal thoughts in young people; vortioxetine, vilazodone and Auvelity all carry it.

Reading the trials behind these approvals

Approval trials answer a narrow question: does the drug beat placebo over a few weeks in carefully selected adults? Vortioxetine's common side-effect data come from placebo-controlled studies lasting 6 to 8 weeks, Auvelity's main efficacy trial ran 6 weeks, and zuranolone's pivotal trials measured the primary outcome at day 15. Long-term relapse prevention, rare side effects and performance in people with several conditions at once are learned more slowly, after approval.

That is why a drug's age matters. Older antidepressants have accumulated evidence across pregnancy, older age, medical illness and many years of use; newer ones have less, simply because less time has passed. It is not a reason to avoid them, but it is a reason to choose one for a specific purpose rather than because it is new.

Side effects in trials also have a time course. Vortioxetine's label notes that its nausea was usually mild or moderate, with a median duration of two weeks, and was more common in women than men. Knowing that a side effect often fades can help you decide, with your prescriber, whether to wait it out or change course.

Cost and coverage, in general terms

Newer drugs are more likely to be brand-only, which affects what you pay. Before a prescription is written, it is reasonable to ask three things: whether a generic version exists, whether your plan covers it and on which tier, and whether prior authorization or a "step therapy" requirement means you must try older drugs first. The step-by-step process is in prior authorization for psychiatric medications, and ways to reduce what you pay are in lowering prescription costs. This is general information, not insurance advice for your plan.

Questions to ask your prescriber

• Why this drug for me, rather than another generic option?
• What side effects led us away from my previous medication, and is this one likely to avoid them?
• How will we know if it is working, and by when?
• Does it interact with anything I take, including over-the-counter cough medicines?
• Will my plan cover it, and what happens if prior authorization is denied?
• For zuranolone: how will I manage the no-driving window, childcare and night feeds during the two-week course?

Never start, stop or switch an antidepressant on your own; switches in particular need a plan for overlap or tapering. If you are thinking about suicide or are in crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or go to the nearest emergency room.

How the practice approaches medication choice

Dr. Lewis's practice provides psychiatric evaluation and medication management alongside psychotherapy, coaching, lab testing, and nutrition and lifestyle psychiatry. If you are weighing a newer antidepressant, medication management at the practice is where that conversation happens, and fees and insurance details are on the insurance and payment page. More comparisons are in the Choosing Psychiatric Care guide.

Frequently asked questions

Is Auvelity a ketamine-like drug?

Both dextromethorphan and esketamine act at NMDA receptors, but they are different drugs with different labels. Auvelity is an oral tablet taken at home for major depression, while esketamine is a nasal spray given only in certified settings under a REMS program.

Can I take zuranolone while breastfeeding?

This is an individual decision with your prescriber and your baby's pediatrician. In a lactation study of 14 women, zuranolone was present in breast milk at low levels, with a mean relative infant dose of 0.357% of the maternal dose, but there are no data on effects in breastfed infants. See psychiatric medications while breastfeeding.

Does vortioxetine cause less weight gain?

Weight gain is not among the most common adverse reactions on its label, which lists nausea, constipation and vomiting. Individual responses vary, so weight is worth tracking with any antidepressant.

Why does vilazodone have to be taken with food?

Food changes how much is absorbed. The label reports that in the fasted state, vilazodone exposure (AUC) can be about 50% lower and peak levels about 60% lower than with food, which is why it is dosed with a meal. Building it into a regular meal helps.

Is a newer antidepressant a good first choice?

Usually not, unless something specific rules out older options. Reviews have not shown greater benefit than established second-generation antidepressants. See how a first antidepressant is chosen.

Sources

1. TRINTELLIX (vortioxetine) tablets prescribing information. Takeda Pharmaceuticals America via DailyMed (U.S. National Library of Medicine), 2025. dailymed.nlm.nih.gov
2. VIIBRYD (vilazodone) tablets prescribing information. Allergan via DailyMed (U.S. National Library of Medicine), 2025. dailymed.nlm.nih.gov
3. AUVELITY (dextromethorphan and bupropion) extended-release tablets prescribing information. Axsome Therapeutics via DailyMed (U.S. National Library of Medicine), 2026. dailymed.nlm.nih.gov
4. ZURZUVAE (zuranolone) capsules prescribing information. Biogen via DailyMed (U.S. National Library of Medicine), 2026. dailymed.nlm.nih.gov
5. FDA Approves First Oral Treatment for Postpartum Depression. U.S. Food and Drug Administration, 2023. fda.gov
6. Sage Therapeutics, Inc.; Withdrawal of Approval of a New Drug Application for ZULRESSO (Brexanolone) Solution. Federal Register (FDA notice, 90 FR 12162), 2025. govinfo.gov
7. Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis. Journal of Affective Disorders (Wagner et al.), 2018. pubmed.ncbi.nlm.nih.gov
8. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet (Cipriani et al.), 2018. pubmed.ncbi.nlm.nih.gov
9. EXXUA (gepirone) extended-release tablets prescribing information. DailyMed (U.S. National Library of Medicine), 2026. dailymed.nlm.nih.gov
10. FETZIMA (levomilnacipran) extended-release capsules prescribing information. Allergan via DailyMed (U.S. National Library of Medicine), 2026. dailymed.nlm.nih.gov
11. SPRAVATO (esketamine) nasal spray prescribing information. Janssen Pharmaceuticals via DailyMed (U.S. National Library of Medicine), 2026. dailymed.nlm.nih.gov

Educational information, not medical, tax or legal advice. Decisions about diagnosis, medication and treatment belong with a clinician who knows your history.